Effect of gene variants on opioid dose, pain and adverse effect outcomes in advanced cancer: an explorative study
- Author(s)
- Wong, AK; Klepstad, P; Somogyi, AA; Vogrin, S; Le, B; Philip, J; Rubio, JP;
- Journal Title
- Pharmacogenomics
- Publication Type
- Online publication before print
- Abstract
- Aim: Associations between gene variants and opioid net effect are unclear. We conducted an exploratory pharmacogenetic analysis of 35 gene variants and opioid response in advanced cancer. Patients & methods: This multi-center prospective cohort study included clinical data, questionnaires (pain and adverse effects) and DNA (blood). Negative binomial regression and logistic regression were used. Results: Within 54 participants, eight statistically significant associations (p = 0.002-0.038) were observed between gene variants and opioid dose, pain scores or adverse effects, the majority being within the neuroimmune TLR4 pathway (IL1B [rs1143634], IL2 [rs2069762], IL6 [rs1800795], BDNF [rs6265]) and ARRB2 pathway (ARRB2 [rs3786047], DRD2 [rs6275]). Conclusion: Neuroimmune pathway genes may contribute to differences in opioid response in cancer and may be included in future similar studies.
- Keywords
- advanced cancer; analgesics; neuroimmune genes; opioid; palliative care; pharmacogenetics
- Department(s)
- Palliative Care
- Publisher's Version
- https://doi.org/10.2217/pgs-2023-0207
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-01-23 03:52:04
Last Modified: 2024-07-30 01:53:01